ResoTher Pharma is extremely pleased to announce our nomination as winner of the European-wide 2019 Advance Biotech Awards, issued by German pharma conglomerate Merck AG. ResoTher Pharma was one of many European contestants for the prestigious award and was selected...

ResoTher Pharma management is pleased to announce that Joel Scherer, MD has joined the company´s Scientific Advisory Board. Dr. Scherer brings considerable drug development and cardiology expertise from his former roles as Chief Medical Officer, Managing Director at...

Kirsten Drejer, PhD takes on the role as Chairwoman of the Board of ResoTher Pharma following a unanimous vote at the company´s general assembly. “We are extremely pleased with the collaboration with Kirsten, who has a wealth of experience to contribute to a company...

The management of ResoTher Pharma is pleased to announce that consulting cardiologist and Professor Thomas Engstrøm, MD joins the company´s scientific advisory board as an expert clinical advisor. Dr. Engstrøm is an expert in the diagnosis and treatment of Myocardial...

Jeppe Øvlesen, Chairman of ResoTher Pharma, is pleased to announce that biotech veteran Kirsten Drejer, PhD joins the Board of Directors effective immediately. Dr. Drejer brings with her significant leadership and company building experience from her many years as...

ResoTher Pharma is pleased to announce the signing of its first round of investment, lead by CAPNOVA A/S and consisting of a handful of private DK and US-based investors. CEO Lone Veng, PhD will take leadership of the new entity, whose goal it is to clinically...